Introduction
The acute leukemias are characterized by aberrant differentiation and proliferation of malignantly transformed hematopoietic stem cells. These cells accumulate within the bone marrow and lead to suppression of the growth and differentiation of normal blood cells. Symptoms result from varying degrees of anemia, neutropenia, and thrombocytopenia or from infiltration into tissues. Although virtually any organ system may become involved once leukemia cells enter the peripheral blood, the lymph nodes, liver, spleen, central nervous system (CNS), and skin are the most common sites detected clinically.
The traditional classification of the acute leukemias has relied most heavily on morphologic and cytochemical characteristics. However, recent advances in immunology, molecular biology, and cytogenetics have substantially enhanced our understanding of the biologic markers that distinguish normal hematopoietic cells from their leukemic counterparts.
Such technologies have firmly advanced the knowledge of leukocyte differentiation and the cellular origins of acute leukemia. Furthermore, these technologies allow for the accurate classification of a malignant clone as myeloid, B lymphoid, T lymphoid, or biphenotypic in most cases.
Advances in cytogenetics have increased our understanding of the association of certain nonrandom chromosomal abnormalities with specific morphologic subtypes of acute leukemia, providing further evidence that genetic changes play a major role in the transformation of a normal cell to a neoplastic one. A number of recurring chromosomal alterations have been identified that carry important prognostic weight with regard to response to chemotherapy and overall survival. Contemporary characterization of any acute leukemia requires the application of immunologic phenotyping, molecular biologic techniques, and cytogenetic analysis, which together complement and expand the more traditional morphologic and cytochemical descriptions of these diseases.
normal hematopoietic counterpart. In 1976, a group of hematopathologists formed the French-American-British (FAB) Cooperative Group with the aim of establishing a subclassification system for the acute leukemias that would clearly separate acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) into distinct disorders. 1 This system was based solely on light microscopic evaluation of routinely stained blood and marrow smears, supplemented by a limited number of cytochemical procedures. Due to its ease of use and applicability when comparing treatment results among institutions, this system has gained widespread adoption. The system was revised in 1985 to provide clarification and extend to new diagnostic techniques. 2 
ACUTE LYMPHOBLASTIC LEUKEMIA
The FAB classification system described three subtypes of ALL (L1, L2, and L3) defined by individual cytologic features such as cell size, nuclear chromatin pattern, nuclear shape, nucleoli, and amount of basophilia in the cytoplasm. The subtype L1, which accounts for over 80 percent of the ALL cases in children and about 30 percent in adults, consists of predominantly small cells, up to twice the diameter of a small lymphocyte. The nuclear chromatin is homogeneous and the nuclear shape is regular. Nucleoli are often not visible, but when detected are inconspicuous. The cytoplasm is scant in amount and is usually only slightly or moderately basophilic. Most adult cases of ALL are L2. These cells are larger than in L1 and are often heterogeneous in size. The nuclear chromatin pattern is heterogeneous as well. Nuclear shape is often irregular and nucleoli are more conspicuous than in L1. The amount of cytoplasm is variable but is often moderately abundant and variably basophilic. The least common type of ALL, seen in about three to four percent of both children and adults, is termed L3. This subtype is morphologically identical to the neoplastic cells in Burkitt's lymphoma. These cells are large and uniform with finely stippled chromatin and regular nuclear shape. Nucleoli are often prominent. Cytoplasm is moderately abundant and deeply basophilic.
The FAB group later recognized that the distinction between L1 and L2 was not always straightforward. To improve reproducibility among observers, a simplified scoring system was adopted that stressed three key features of the blast cell population: nuclear/cytoplasmic ratio (N/C), visibility of nucleoli, and presence or absence of an irregular nuclear membrane. 3 Cell size was considered important only if 50 percent or more of the leukemia cells were large.
Cytochemical evaluations of blast cells in ALL reveal characteristic patterns. By definition, the Sudan black reaction or stains for lysosomal enzymes, such as myeloperoxidase, must be negative to support a diagnosis of ALL. The periodic acid-Schiff reaction will reveal clumpy positivity due to glycogen in ALL blasts (except L3, which reacts negatively) but is a poor discriminator of cell lineage as many AML cells will also react positively. Chloroacetate esterase and lysozyme stains are negative, but α-naphthyl acetate esterase may be positive in T lymphoblasts. The blast cells of over 90 percent of patients with ALL contain the enzyme terminal deoxynucleotidyl transferase (TdT). L3 leukemia cells often stain positively with oil red O due to neutral lipids within the cytoplasmic vacuoles.
ACUTE MYELOID LEUKEMIA
The blast cells of patients with AML are most often larger than lymphoblasts and display a greater heterogeneity in size and shape. AML blasts have more abundant cytoplasm and usually contain cytoplasmic granules. Auer rods, azurophilic crystalline-like accumulations of abnor-
M3
Leukemia cells usually contain heavy azurophilic granulation. Nuclear 8-15 size varies greatly. Nuclei are often bilobed or kidney-shaped. Some cells contain bundles of Auer rods. Leukemia cells stain strongly positive for myeloperoxidase. There is a micro-granular variant
M4
Myeloblasts, promyelocytes, myelocytes, and other granulocytic 20-25 precursors make up over 30% of the nonerythroid cells but do not exceed 80%. Monocytic cells account for up to 20% of the nonerythroid cells. Nonspecific esterase and chloroacetate stains are often positive. Auer rods may be present
M4Eo
Myelomonoblasts with cytochemically and morphologically abnormal 5 eosinophils
M5
Monoblasts, promonocytes, or monocytes make up 80% or more of the nonerythroid cells. In one subtype (M5a), 80% or more of all the monocytic cells are monoblasts. In the well-differentiated subtype (M5b), less than 80% are monoblasts. Naphthol AS-D acetate positivity is extinguished by sodium flouride
M6
Greater than 50% of the nucleated marrow cells are erythroid. Erythroblasts 5 are usually strongly positive for the periodic acid-Schiff reaction.
Myeloblasts represent 30% or more of the nonerythroid cells
M7
Large and small megakaryoblasts with high nuclear/cytoplasm ratio. 1-2 Cytoplasm is pale and agranular. Standard cytochemical stains not definitive. Platelet peroxidase and platelet-specific antibodies often positive (Table 1) , including three types with predominantly granulocytic differentiation (M1, M2, and M3), two with at least 20 percent monocytic precursors (M4, M5), one with a high proportion of erythroblasts (M6), and a more recently recognized and rarely occurring variant with a predominance of megakaryoblasts (M7). In addition, the FAB group has described a form of AML with minimal myeloid differentiation, designated M0, which cannot be diagnosed solely on morphologic or cytochemical grounds but also requires the use of immunohistochemical staining. 4 These cases express myeloid antigens on the blast cell surface but lack myeloperoxidase activity.
Immunobiology of Acute Leukemia
About 80 percent of ALL arise from the B-cell lineage. 5 Most of these cases express the common ALL antigen or CALLA, recently designated CD10. Such cells also express other B-cell differentiation antigens (CD19 and CD20) and have undergone immunoglobulin heavy and/or light chain gene rearrangements. These CD10-bearing cells can be further divided based on the presence of cytoplasmic immunoglobulin. Most cases do not express cytoplasmic immunoglobulin and are termed early B-precursor ALL. About 20 percent of cases express cytoplasmic immunoglobulin and are designated pre-B ALL. Surface immunoglobulin expression occurs in only two to five percent of ALL cases; these are termed mature B-cell ALL and typically display the FAB L3 morphology.
From 15 to 20 percent of ALL cases arise from the T-cell lineage. These cells express T-cell antigens such as CD5 and CD7; CD10 may be present. In most cases, one or more of the T-cell receptor genes is rearranged. Further subclassification of T-cell ALL into early, intermediate, or mature thymocyte types is based on the expression of various T-cell differentiation antigens. A very small percentage of ALL cases lack either B-or T-cell features and are termed null-cell ALL. Certain antigens normally found only on myeloid cells can be expressed by malignant lymphoblasts of either B-or T-cell origin. These cases are called myeloid antigen positive ALL. A simplified immunologic subclassification of ALL is provided in Table 2 .
As yet, no AML-specific surface antigens have been identified. Rather, AML cells often express antigens simultaneously on the cell surface that are not normally coexpressed by their normal myeloid counterparts. Efforts to correlate immunologic phenotyping with the FAB classification of AML or with clinical outcome have in general been imprecise. However, the expression of certain antigens such as CD34, an early stem-cell marker, may carry important prognostic information. 6 
HYBRID LEUKEMIAS
Recent application of both immunoanalysis and molecular probes has uncovered a number of cases in which leukemia cells display characteristics of both myeloid and lymphoid cells. In such instances, a single neoplastic cell may coexpress features of distinct lineages (biphenotypic) or, alternatively, two distinct subpopulations of leukemia cells may express either myeloid or lymphoid features separately (bilineal). Various theories have been put forward to explain the occurrence of these hybrid leukemias. One hypothesis, termed lineage infidelity, states that the leukemia cell displays aberrant gene expression by virtue of its neoplastic transformation. Another theo-ry, lineage promiscuity, proposes that normally differentiating cells may express characteristics of more than one distinct lineage and that the leukemic cell is merely reflecting that particular phase in a cell's development. Finally, a theory termed lineage switching proposes that in some cases leukemia is a malignancy of a pluripotent stem cell capable of differentiation along either a myeloid or lymphoid lineage. Thus, any individual case may express one or both phenotypes.
Investigators have attempted to understand the clinical significance of hybrid leukemias. A report by the Cancer and Leukemia Group B (CALGB) evaluated the prognostic value of lymphocyte surface markers in AML among 339 newly diagnosed patients enrolled in chemotherapy protocols. 7 When treatment outcome among these lymphocyte-antigen-positive cases was compared with the lymphocyte-antigen-negative cases, a higher complete remission rate, longer time to treatment failure, and better overall survival were noted among lymphocyte-antigen-positive patients. Conversely, in several series, patients with TdT-positive AML have experienced lower complete remission rates, less durable remissions, and worse overall survival. 8, 9 Thus, the true prognostic significance of AML cases bearing lymphocyte markers requires further clarification.
Less data are available regarding the importance of myeloid antigen expression (CD13, CD33) in adult ALL. An early study determined myeloid antigen expression to be an independent predictor of poor response to chemotherapy in childhood ALL. 10, 11 Myeloid antigen expression was examined in 76 adult cases of ALL and was present in about one third of patients. 12 Although no significant differences in clinical presenting features were noted, a significantly lower incidence of complete remission ( 
Cytogenetics
Cytogenetic abnormalities occur commonly in the acute leukemias. Since the application of chromosome banding techniques in the early 1970s, cytogenetic analysis has provided the most clinically useful approach to subclassifying the acute leukemias. Syndromes of acute leukemia have been well described in which a particular nonrandom chromosomal abnormality correlates with a specific morphologic subtype and clinical picture. Such recurring chromosomal abnormalities have provided important information regarding response to therapy and overall prognosis.
Cytogenetic analysis has furthered our understanding of leukemogenesis. Careful analyses of the chromosomal breakpoints have permitted identification of a number of genes that appear to play an integral role in leukemogenesis. The chromosomal location of a large number of these oncogenes has been identified. Although little is presently known about the function of these oncogenes, many are believed to be involved in the control of cellular proliferation and differentiation. Structural chromosomal changes may lead to activation or perturbation of oncogene expression resulting in disturbance of cellular regulation and eventually malignant transformation.
ACUTE MYELOID LEUKEMIA
Clonal chromosomal abnormalities can be detected in most cases of AML. These abnormalities include gains or losses of whole chromosomes or the long (q) or short (p) arms of chromosomes as well as a variety of structural rearrangements (translocations, inversions, or insertions).
It is strongly recommended that cytogenetic analysis prior to initiation of therapy be performed on every newly diagnosed patient because studies of the prognostic significance of recurring cytogenetic abnormalities in AML have yielded consistently similar results. Thus, in many centers plans for postremission therapy currently rely heavily on cytogenetic analysis at diagnosis.
Acute Myelogenous Leukemia with Maturation (FAB M2) and t(8;21)(q22;q22)
This syndrome occurs in about five percent of all AML cases and most often affects young adults. 15, 16 Morphologically, the translocation t(8;21) is almost invariably associated with FAB type M2. The leukemia cells are heterogeneous in size, often with prominent Auer rods and a waxy, salmon-colored cytoplasm. The marrow frequently has increased numbers of eosinophils. This syndrome is associated with the most favorable prognosis. These patients have a high rate of complete remission (85 to 100 percent), and many patients are cured using conventional chemotherapy.
Acute Promyelocytic Leukemia (FAB M3) and t(15;17)
Acute promyelocytic leukemia (APL) is associated with disseminated intravascular coagulation at diagnosis or soon after initiation of treatment. The age distribution is bimodal; most patients are young adults, but the disease is also seen in the elderly. A structural rearrangement involving chromosomes 15 and 17 is present in both the hypergranular form and the less common microgranular variant. 17 The peripheral white blood cell (WBC) count is usually not high and is often low (typically <5,000/µl). Circulating APL cells are not always apparent. Patients with this syndrome typically achieve a high rate of complete remission and many are cured. A unique characteristic of this syndrome is that the leukemia cells can be induced to differentiate into mature granulocytes following exposure to differentiating agents such as all-transretinoic acid (TRA). 18 Acute Myelomonocytic Leukemia with Abnormal Eosinophils (FAB M4Eo) and inv (16) 
or t(16;16)
About five percent of patients with AML de novo have blasts with myelomonocytic features (M4) but also have morphologically and histochemically abnormal eosinophils. 19 Sometimes the total number of eosinophils is increased. The syndrome is invariably associated with abnormalities involving both arms of chromosome 16, most often a pericentric inversion, inv(16)(p13q22), but also the translocation t(16;16)(p13;q22). These patients have a high rate of complete remission and a good outcome. Interestingly, one study noted a high rate of CNS relapse (35 percent), but this has not been confirmed by other investigators, perhaps due to the use of high-dose cytarabine consolidation therapy. 19 
Acute Monoblastic Leukemia (FAB M5) and Rearrangements of 11q
The association between abnormalities involving the long arm of chromosome 11 (11q) and acute monoblastic leukemia (M5) has been noted by a number of investigators. Most of these patients fit best into the M5a category with poorly differentiated monoblasts. While several different chromosomes may act as donors in reciprocal rearrangements with 11q, the t(9;11)(p21;q23) is the most frequently noted. Most of these patients are children or young adults who often have skin or gums infiltrated by leukemia cells. Patients with this syndrome frequently enter remission, but remissions may be short.
Acute Myeloid Leukemia with Abnormal Thrombocytopoiesis and Rearrangements of 3q
Some AML patients with structural abnormalities of the long arm of chromosome 3(3q) display abnormal thrombocytopoiesis, presenting either with increased platelets (occasionally >1,000,000/µl) or increased marrow megakaryocytes with dysplastic features. 20 Most cases are subtyped as M2, M4, or M6. Although few of these patients have been reported on, initial data suggest a poor prognosis for this category.
Acute Myeloid Leukemia with Bone Marrow Basophilia and t(6;9)
A balanced translocation between chromosomes 6 and 9 has been described with an increased proportion of bone marrow basophils (1.5 to 12 percent). These cases represent fewer than two percent of AML and are not associated with any particular morphologic subgroup. These patients are typically young adults and as a group have responded poorly to conventional chemotherapy.
ACUTE LYMPHOBLASTIC LEUKEMIA
Up to 90 percent of cases of childhood ALL have been found to have one or more karyotypic abnormalities. 21 Numerical chromosomal changes occur more frequently in ALL than in AML. The modal number, which is the most common chromosome number within the cell population, is examined first. When the mode is less than 46, the clone is referred to as hypodiploid; if greater than 46, then hyperdiploid. Karyotypes with normal chromosome number but with structural and/or numerical changes are termed pseudodiploid. Numerical chromosomal changes influence prognosis, with high hyperdiploid cases (>50 chromosomes) having a longer median survival compared with patients with an apparently normal karyotype.
Despite the importance of numerical chromosomal changes for prognosis, recent attention has focused on the impact of recurring structural chromosomal rearrangements in ALL. Over 15 different recurring structural aberrations have been detected. Structural rearrangements are present in about two thirds of all cytogenetically abnormal cases, and many are associated with particular hematologic and immunophenotypic characteristics.
The Philadelphia Chromosome
About five percent of children and 25 to 33 percent of adults with ALL have the Philadelphia (Ph) chromosome, which refers to the abnormal chromosome 22 that results from the balanced translocation, t(9;22)(q34;q11). 22 Part of the ABL proto-oncogene on chromosome 9 is transferred to a point within the breakpoint cluster region (BCR) gene on chromosome 22, resulting in a chimeric BCR-ABL fusion gene. Depending upon where the translocation of ABL occurs in the BCR gene, the chimeric gene expresses a protein of either 190 or 210 kilodaltons (kd), both of which possess increased tyrosine kinase activity in comparison with the normal ABL gene product. The exact role of this fusion gene product in the pathogenesis of Ph chromosome-positive (Ph + ) ALL is unclear. Molecular methods that may be more sensitive than cytogenetic analysis for the detection of the BCR-ABL translocation have detected this rearrangement in greater than 30 percent of all adults with ALL and half of all B-lineage cases. 23 Two thirds of adult cases have the same gene rearrangement expressing the 190-kd protein as in childhood ALL while one third express the 210-kd protein characteristic of chronic myelogenous leukemia. 24 
Ph
+ ALL usually has FAB L2 morphology but may occasionally be L1. The phenotype reveals immature B-cell differentiation. Patients with Ph + ALL now appear to respond well to induction chemotherapy but have significantly shorter remission durations and survival compared with patients without this translocation. 13 
4;11 Translocation
Translocation t(4;11)(q21;q23) occurs in about five percent of cases of ALL and is equal in frequency among infants (younger than one year) and adults. 25 Most of these cases display the L1 or L2 morphology and mark as early B cells. However, both lymphoid and myeloid features are found after examination of their ultrastructural character and cytochemical staining patterns, suggesting bilineage differentiation. These patients often have splenomegaly and a high leukocyte count (over 40,000/µl) at diagnosis. The overall prognosis is poor due to short duration of remission.
8;14 Translocation
The translocation t(8;14)(q24;q32) was first identified in patients with Burkitt's lymphoma. 26 The same translocation has been detected in ALL patients whose leukemia cells possess surface immunoglobulin and the FAB L3 The WBC count is elevated in one third of patients, but in recent years counts of greater than 100,000/µl occur in less than 10 percent of patients, probably due to earlier diagnoses. The peripheral blood will contain some leukemic blast cells in 85 to 90 percent of cases. The absolute granulocyte count is almost always depressed in AML and is less than 1,500/µl in half of patients at diagnosis. A moderate degree of anemia is common, and the platelet count is typically less than 100,000/µl and often less than 20,000/µl.
Mild to moderate elevations of serum uric acid levels are common and typically reflect increased cell turnover. The serum lactate dehydrogenase level may be elevated but not as commonly as in ALL. Muramidase (lysozyme) is elevated in the serum or urine of patients with acute myelomonocytic or monoblastic leukemias.
AML is not limited to the bone marrow and peripheral blood. Abnormalities in one or more organ systems may result from leukemia-cell infiltration or metabolic complications related to leukemia. Rarely, a patient with AML will develop a solid mass of leukemia cells called a granulocytic sarcoma. The skin and bones, particularly sternum, ribs, or orbit, are most commonly involved, but granulocytic sarcomas can occur in any organ. Respiratory distress in patients with AML is most often due to infection. However, patients with very high numbers of circulating blast cells (>100,000/µl) may develop severe dyspnea and hypoxemia due to leukostasis within the pulmonary capillaries. Cardiac dysfunction, including murmurs, congestive heart failure, and dysrhythmias, are most often secondary to anemia.
Retinal hemorrhages are most often due to thrombocytopenia. However, patients with extreme hyperleukocytosis may develop "cotton wool" spots due to retinal ischemia. Frank CNS involvement and cranial neuropathies are unusual at initial diagnosis of AML.
CLINICAL FEATURES OF ACUTE LYMPHOBLASTIC LEUKEMIA
ALL accounts for about 20 percent of adult acute leukemias. The clinical presentation in adults is most often acute; symptoms are usually present for only a few weeks prior to diagnosis. Malaise, lethargy, weight loss, fever, and night sweats may be present but are typically not severe. Bone pain and arthralgias occur occasionally but much less frequently in adults than in children. Infection and hemorrhage are present in one third of patients at diagnosis. Lymphadenopathy, splenomegaly, and hepatomegaly are more common than in AML, affecting half of adults with ALL. Chest radi-ographs may reveal a thymic mass in 15 percent of adults. Most of these patients have T-cell ALL.
CNS involvement by leukemia occurs in five to 10 percent of adult cases. Cranial nerve palsies most often involve the sixth and seventh cranial nerves. Headache and papilledema resulting from meningeal infiltration and obstruction of the outflow of cerebrospinal fluid with raised intracranial pressure may be present. Retinal hemorrhages may be the result of thrombocytopenia.
Varying degrees of neutropenia, anemia, and thrombocytopenia are detected on the peripheral blood examination. In one series of over 1,200 adult cases, the granulocyte count was below 1,500/µl in only one fifth of the patients. 28 Mild to moderate reductions in hemoglobin level were typical, but almost one third of patients had a hemoglobin level below 8 g/dl. Thrombocytopenia was frequent and over one half of patients had a platelet count below 50,000/µl. The total WBC count was diminished in about one 
Treatment of Acute Myeloid Leukemia
The aim of antileukemia therapy is to eradicate the neoplastic cells and restore normal hematopoiesis. Therapy is divided into several stages. The first is termed remission induction and is designed to reduce the leukemia cell burden below the level of detection (i.e., from about 10 12 to less than 10 8 to 10 9 malignant cells remaining in the body). By definition, complete remission refers to a state where no leukemia cells are detected in the bone marrow and the peripheral blood counts have returned to normal. It is generally assumed, however, that a substantial burden of leukemia cells persists undetected, leading to relapse within a few weeks or months if no further therapy were administered.
Three treatment strategies have been pursued for postremission therapy. Consolidation therapy or early intensification refers to the administration of chemotherapy that is the same, more intense, or non-cross resistant to the chemotherapy used during induction. Each course of consolidation may produce profound myelosuppression. Maintenance chemotherapy is treatment that is generally less myelosuppressive and is administered frequently over several months or years, usually on an outpatient basis. In certain instances, intensive myeloablative chemotherapy or chemoradiotherapy followed by marrow transplantation from an appropriate donor is used following remission induction. Controversy exists regarding the most effective postremission strategy. Most investigators in the United States believe that maintenance therapy has not increased the cure rate in AML patients who have already received intensive induction and consolidation chemotherapy. 29 
REMISSION INDUCTION
Remission induction chemotherapy for AML has not changed significantly in over a decade. The two standard drugs are daunorubicin (DNR) and cytarabine (ara-C). DNR administered over three days together with seven days of "conventional-dose" ara-C (100 to 200 mg/m 2 per day) results in complete hematologic remission in 70 percent of patients younger than 60 years. [29] [30] [31] The substitution of doxorubicin for DNR in a randomized trial resulted in greater gastrointestinal toxicity without an improved remission rate. 32 The addition of a number of other chemotherapy agents to this two-drug regimen has generally resulted in increased toxicity without improving either remission rate or duration. Thus, this "3 + 7" combination of DNR and ara-C has become the standard remission-induction regimen against which all others are compared (Table 3) .
A substantial proportion of patients achieving complete remission are unable to receive further postremission therapy due to persistent toxicity from induction therapy (lingering bacterial or fungal infection, poor performance status and nutrition, or hepatitis). Thus, the aggressiveness of any induction regimen must be balanced against toxicities that may preclude further therapy. Inability to receive postremission therapy leads to early relapse.
It might be expected that high-dose ara-C would further reduce the leukemia cell burden during induction without significantly prolonging the period of myelosuppression. When Phillips et al administered twelve doses of high-dose ara-C (3 g/m 2 ) combined with three days of DNR to 70 young adults, 90 percent achieved complete remission. 33 Unfortunately, only 40 of 63 patients were able to receive the planned postremission consolidation because of persistent chemotherapy-related toxicity in the remaining patients. Eight patients were selected to undergo BMT in first remission. Thus, while 90 percent of patients achieved complete remission, only 76 percent received further chemotherapy or BMT, and only 27 percent of patients became long-term disease-free survivors. Other trials suggest that high-dose ara-C has not improved AML induction therapy. 34 Bishop et al have reported that the addition of etoposide to standard ara-C/DNR treatment resulted in a significantly better remission duration. 35 Mitoxantrone has also been reported to be a more effective inducer of remission than DNR. 36 Both reports require confirmation. In one randomized trial, amsacrine was compared to DNR. 37 Patients receiving amsacrine had a higher remission rate and longer survival. However, a second randomized trial did not confirm this result. 38 Idarubicin is a DNR analogue with possible advantages over DNR because its metabolite idarubicinol has a long half-life and is active against leukemia cells. Several randomized multicenter trials have compared ara-C plus idarubicin with ara-C plus DNR for remission induction and consolidation. 39, 40 Certain subsets, for example younger adults or those with an initial WBC count greater than 50,000/µl, appeared to have a better complete remission rate and remission duration than those who received DNR, but the benefits were not consistently observed in all trials.
POSTREMISSION THERAPY
Continued cytoreductive therapy is required to prevent relapse of AML. Intensive, early consolidation treatment appears superior to either maintenance or late intensification strategies. A number of nonrandomized trials have suggested that patients receiving high-dose ara-C for consolidation therapy have longer remissions compared with those receiving standard-dose ara-C. 41 , 42 Wolff et al have reported that one to three courses of consolidation therapy with high-dose ara-C and DNR produced an actuarial probability of remaining in remission of 40 percent, with a median follow-up of longer than three years. 41 Case selection and age markedly influenced disease-free survival; patients younger than 25 years had an 83 percent probability of remaining in remission, but the rate declined sharply with advancing age. The number of postremission cycles did not influence survival although data suggested an advantage to receiving more than one course of high-dose consolidation.
At the University of California, Los Angeles (UCLA), 40 patients younger than 60 years received high-dose ara-C and DNR followed by a second course of standard-dose ara-C and DNR. 42 Disease-free survival was 36 percent and was significantly better than observed in a previous UCLA trial where only standard doses of ara-C were given as consolidation therapy.
In a trial by the CALGB, AML patients in first complete remission were randomized to receive consolidation with four courses of high-dose ara-C (3 g/m 2 for six doses) versus an intermediate dose (400 mg/m 2 per day) versus the standard dose (100 mg/m 2 per day). 43 For patients younger than 40 years, those in the highdose and intermediate-dose ara-C arms have had significantly longer remissions and survival. For those aged 40 to 60 years, the high-dose ara-C arm was the best. For those older than 60 years, the three different dose regimens had equivalent responses.
The addition of new, potentially non-cross-resistant drugs to high-dose ara-C regimens is now being tested in many centers. Amsacrine, etoposide and cyclophosphamide, and mitoxantrone with diaziquone or etoposide have yielded encouraging initial results. 44, 45 The true effectiveness of such regimens re-mains to be determined as does the identification of particular subgroups of patients more likely to benefit from one rather than another treatment.
Allogeneic Bone Marrow Transplantation
Another postremission strategy uses marrow-ablative chemotherapy or chemoradiotherapy followed by infusion of marrow from an HLA-identical donor, most often a sibling. Successful BMT regimens must be immunosuppressive in addition to being antileukemic. The use of allogeneic BMT in AML patients in first remission has reduced the relapse rate from 60 percent to about 15 to 25 percent when compared with conventional chemotherapy. 46 Unfortunately, this high degree of disease control is offset by a treatmentrelated mortality of 20 to 25 percent in adult recipients due both to graft-versushost disease (GVHD) and to treatment toxicity. Thus, disease-free survival for AML patients in first remission ranges from 40 to 60 percent following allogeneic BMT depending in part on the age of the patient. Older age is associated with lower survival.
One component of the antileukemic benefit afforded patients undergoing allogeneic BMT is known as the graftversus-leukemia effect. This is an immune phenomenon in which certain donor lymphocytes are believed to recognize and eradicate residual host leukemia cells, providing additional antileukemia effect to that achieved by the preparative regimen. 47 Efforts aimed at diminishing GVHD, such as T-cell depletion of the donor marrow, have unfortunately led to increased rates of relapse following allogeneic BMT. 46 Thus, a moderate degree of GVHD may be beneficial for its antileukemia activity.
Various transplant preparative regimens have included high-dose etoposide with total body irradiation (TBI) and the use of nonradiation-containing regimens. 48, 49 Busulfan and cyclophosphamide (Bu/Cy) in patients with AML in first remission has demonstrated lower treatment-related mortality while maintaining a relapse rate below 20 percent. 49 An event-free survival of 63 percent has been reported for 71 patients in first remission. However, a recent randomized trial comparing Bu/Cy to cytoxan/TBI actually revealed less treatment-related mortality and improved relapse-free survival in the arm with TBI. 50 The superiority of one preparative regimen over another remains unproven. Figure 1 compares survival curves for patients transplanted for AML by age groups and by various disease states.
Further advances in the area of allogeneic BMT, including the fractionation of TBI, more effective GVHD prophylaxis, and early recognition and treatment of cytomegalovirus infections, have produced improvements in disease-free survival. 51 Still, treatment-related toxicity generally limits this procedure to patients younger than 60 years. In addition, only about 25 to 30 percent of eligible patients will have an HLA-identical sibling donor. Thus, although the results of allogeneic BMT for selected patients with AML in first remission have been impressive, the procedure remains limited to a minority of patients. With the development of a national bone marrow donor registry, investigators have attempted to expand the availability of BMT by using HLA-identical but unrelated donor marrow. 52 Too few patients with AML in first remission have undergone marrow transplantation using unrelated donors to comment on its general feasibility. However, the high incidence of moderate to severe GVHD makes this option risky for such patients.
Autologous Bone Marrow Transplantation
In contrast to allogeneic BMT, any patient younger than 60 years who enters complete remission is potentially eligible 
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for an autologous BMT procedure. The principles of this treatment strategy are simple. Following harvesting and cryopreservation of the patient's own remission bone marrow, myeloablative doses of chemotherapy with or without radiation are administered. Then, the patient's stored marrow cells are thawed and reinfused and allowed to repopulate the emptied marrow space. Thus, the patient serves as his own marrow donor. In addition, lack of any GVHD or prolonged immunosuppression markedly reduces treatment-related mortality. However, there are some cautions regarding this therapy. Relapse rates following autologous BMT are clearly greater than that following allogeneic BMT due to the loss of the graft-versus-leukemia effect and possibly due to marrow contaminated with residual leukemia cells being reinfused following chemotherapy. 53 In an effort to eradicate or purge residual leukemia cells from harvested marrow prior to freezing, chemotherapeutic drugs with or without monoclonal antibodies 54 Unfortunately, patients receiving purged marrow may experience a delay in marrow engraftment due to damage to stem cells by the purging agents. [55] [56] [57] [58] [59] Randomized trials comparing conventional chemotherapy versus allogeneic or autologous BMT continue to accrue patients. Those patients with favorable prognostic features who do well with chemotherapy also do well with transplantation. It remains to be determined whether the larger group of patients who do poorly with chemotherapy alone will have any better survival following transplantation. In general, the studies reported to date indicate a decreased risk of relapse in patients treated with BMT. [60] [61] [62] However, only three studies showed a significant advantage in terms of diseasefree survival for patients scheduled to receive BMT, and only one shows an overall survival advantage to BMT. [60] [61] [62] In one recent trial, the availability of an HLAidentical sibling donor was not associated with increased survival. This was due both to efficient salvage treatment of patients relapsing following consolidation chemotherapy and to the inability of some patients with a donor to receive BMT. 63 Therefore, this issue remains controversial. Various options for postremission therapy for adult AML patients are presented in Table 4 .
Relapsed/Refractory Acute Myeloid Leukemia
Despite improvements in the chemotherapy and supportive care of patients with AML, most patients still relapse and ultimately die from their disease. In addition, a number of patients never achieve remission with conventional chemotherapy. Many patients, and particularly those with long first remissions, can achieve a second complete remission should they experience relapse. A variety of new agents such as idarubicin, carboplatin, taxol, homoharringtonine, tiazofurin, diaziquone, and 2-chlorodeoxyadenosine have demonstrated activity in relapsed or refractory AML. 53 High-dose ara-C, with or without additional agents such as DNR, mitoxantrone, etoposide, or amsacrine, appears to be the most effective salvage regimen. 53 High-dose ara-C and etoposide produced complete remissions in over 60 percent of relapsed/refractory patients in one trial. 45 High-dose etoposide and cyclophosphamide produced a complete-remission rate of 42 percent in patients with refractory AML, including a large proportion of patients resistant to high-dose ara-C. 64 AML that is refractory to initial induction chemotherapy or that relapses within six months of remission is not likely to be cured with conventional chemotherapy. If a suitable marrow donor can be found, marrow-ablative therapy followed by allogeneic transplantation should be employed.
Treatment of Acute Lymphoblastic Leukemia
Major advances in the treatment of adult ALL have occurred over the past decade. The prognosis for such patients has clearly improved with the employment of more-intensive treatment strategies. At present, 80 percent of patients achieve a complete remission and over one third of these become long-term disease-free survivors. 13, 53 Similar to AML, treatment of ALL is divided into two major phases: remission induction and postremission therapy. In most instances, ALL induction regimens are less toxic than those used for AML and hence a greater proportion of adult patients achieving complete remission will be capable of receiving postremission treatment. The combination of vincristine and prednisone forms the foundation of virtually all adult ALL induction regimens. Together, these agents produce a response rate of 40 percent. 65, 66 However, despite further postremission treatment, the remission durations using these agents alone for induction have been only three to 12 months. Additional drugs are necessary, such as DNR or doxorubicin, l-asparaginase, and cyclophosphamide. In a randomized trial, the CALGB demonstrated that the addition of DNR to vincristine, prednisone, and l-asparaginase increased the complete response rate from 47 to 83 percent. 67 It is unclear whether the addition of high doses of methotrexate or ara-C during induction improves either remission rate or duration. Certain high-risk subsets may benefit from such approaches. 68 Intensification of induction therapy followed by hematopoietic growth factor support may improve overall prognosis by rapidly eliminating a greater burden of leukemia cells prior to the development of resistance to selected drugs. 69 The central nervous system is an important site of involvement by ALL. Although uncommonly found at diagnosis, CNS involvement is common at the time of relapse. The meninges may harbor leukemia cells, and the blood-brain barrier may shelter them from systemic chemotherapy. Recurrence within the CNS usually coincides with systemic relapse. Preventive treatment of the CNS during postremission therapy, termed CNS prophylaxis, has become an integral part of virtually all current adult ALL treatment protocols. 68, [70] [71] [72] Although the true value of CNS prophylaxis in adults is controversial, studies in which adult patients either refused or could not receive CNS prophylaxis have demonstrated a higher rate of CNS relapse compared with those receiving prophylaxis. 73 CNS leukemia is more easily prevented than treated because once overt CNS leukemia has developed, there is a high likelihood of subsequent CNS relapse despite treatment.
CNS prophylaxis typically consists of cranial irradiation plus intrathecal methotrexate. Ara-C and hydrocortisone are occasionally added to the methotrexate for "triple therapy." In addition, some investigators have substituted high-dose systemic chemotherapy with either methotrexate or ara-C because therapeutic levels of these drugs can be achieved in the cerebrospinal fluid when administered intravenously in high doses. Overall, the superiority of any one prophylactic therapy has not been established.
Critical appraisal of the impact of each component of postremission therapy on disease-free survival in any given trial is difficult for many reasons. There are few well-controlled randomized studies analyzing the importance of individual treatment components on outcome. Changes in treatment protocols are rarely made in a stepwise fashion. Rather, changes in postremission therapy are often made simultaneously with new induction regimens. New drugs have been introduced along with other changes, making their impact on outcome difficult to discern. At present, the benefit of new drugs such as etoposide or teniposide, high-dose ara-C, or mitoxantrone cannot be critically evaluated. Because two thirds of patients with ALL have gene rearrangements, these should serve as useful markers for residual disease. 69 A summary of clinical studies of intensive induction and postremission therapies is provided in Table 5 .
Various patient characteristics at diagnosis have prognostic value with regard to either the achievement of remission or remission duration. 68, 74 Patients presenting with a WBC count greater than 30,000/µl have had significantly shorter durations of remission in multivariate analyses compared with patients with lower leukocyte counts. Older age (>60 years) is another adverse characteristic. Remission duration and overall survival have decreased in almost every adult ALL trial as the age of the patient groups Patients with mature B-cell (Burkitt type) ALL have historically had a poor prognosis. However, very encouraging results have been obtained in children and small numbers of adults with advanced Burkitt leukemia or lymphoma with strategies using high doses of cyclophosphamide, ifosfamide, and methotrexate in combination with other active agents early in the course of treatment. 75, 76 Perhaps the most important of the adverse prognostic features is the presence of certain karyotypic abnormalities, especially the translocations t(9;22), t(4;11), t (8;14) , and their variants. 68, 74 Although remission rates in these patients are not markedly different compared with other ALL subsets, remission durations are usually short and almost all ultimately relapse. The high prevalence of the Ph chromosome subtype, which increases with age, among adult ALL patients is a major reason for the poor outcome in older patients.
Currently, treatment strategies are being designed based on certain prognostic features at diagnosis. A large proportion of adult ALL patients have no adverse characteristics at diagnosis. This group of "favorable" adult ALL patients have a good prognosis with currently available intensive therapies; about 60 percent of such patients have prolonged disease-free survival. T-cell ALL may now be a favorable subset. In contrast, patients with one or more unfavorable prognostic characteristics may not be curable with current conventional chemotherapy. For such patients, more aggressive treatment strategies, including bone marrow transplantation in first remission, are appropriate.
RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA More than half of adult patients with ALL relapse despite modern chemotherapy. 68, [70] [71] [72] Most relapse within the first two years. Over 80 percent of relapses occur first in the bone marrow, while the remainder occur in extramedullary sites, primarily the CNS. Relapses in other sites such as lymph nodes, skin, or testes occur much less frequently. Patients with isolated extramedullary relapse have a very high risk for subsequent bone marrow relapse and should receive systemic chemotherapy following local treatment.
A variety of treatment protocols have been employed in relapsed or refractory patients. High-dose ara-C with or without additional agents produces complete remissions in about 50 percent of patients with relapsed or refractory ALL. 53, 77 However, in almost every instance, the median remission duration has been less than six months and only a small fraction of these patients become long-term survivors. The best results for such patients have been obtained with allogeneic BMT in second remission.
BONE MARROW TRANSPLANTATION
The role for allogeneic BMT in the treatment of adult ALL patients in first remission is controversial. Disease-free survival rates for ALL patients transplanted in first remission range from 30 to 50 percent depending on patient characteristics at entry as well as certain supportive-care measures. 53 When various prognostic characteristics are considered, it is not clear whether allogeneic bone marrow transplantation offers a survival advantage over conventional chemotherapy for patients with a "favorable" prognosis. The International Bone Marrow Transplant Registry performed a retrospective review of BMT results versus intensive consolidation chemotherapy for adults with ALL in first remission. 78 While relapse rates were lower among those transplanted, this advantage was offset by a high rate of transplant-related mortality, and thus, overall disease-free survival was comparable. Many of the factors that predicted poor outcome with conventional chemotherapy also adversely affected the outcome with BMT. One shortcoming of this study was the failure to evaluate cytogenetic subgroups adequately. Given the very poor outcome for Ph + ALL patients following standard chemotherapy and encouraging data for such patients undergoing BMT, it would appear that most of these patients who have a suitable marrow donor should undergo BMT while in first remission.
Data from several transplant centers have reported disease-free survival of about 30 percent at three years for selected ALL patients in second remission. 79, 80 Data for patients with refractory ALL have in general been worse, although a recent report by the International Bone Marrow Transplant Registry suggests over 20 percent of such patients may be long-term survivors following BMT. 81 Also, preliminary data suggest a high response rate for patients with primary refractory ALL who undergo BMT following high-dose etoposide and TBI. 48 Adult patients with refractory or relapsed ALL who are young and have a suitable donor should undergo allogeneic BMT. Figure 2 compares survival curves for patients transplanted for ALL by age group and disease state.
Autologous bone marrow reinfusion (ABMR) is a consideration for patients too old to tolerate an allogeneic transplant or for those who lack an HLA-compatible donor. 82 As in AML, a major concern remains the high likelihood of residual leukemia cells within the harvested, cryopreserved remission marrow. Generally, results with ABMR for ALL have been inferior to those with AML, predominately due to the inability to effectively eradicate minimal residual disease at the time of marrow harvest. For young adult ALL patients in first remission who have high-risk features, consideration for high-dose chemotherapy and unrelated donor marrow transplantation should be made.
Future Directions
Despite major advances in the treatment of adult patients with acute leukemia in the past decade, most patients continue to die either from their disease or the complications of its treatment. However, a number of novel experimental and clinical approaches hold promise for improving cure rates in patients with acute leukemia.
In recent years, the biologic heterogeneity of these diseases has been further defined. A variety of clinical and laboratory parameters have been reported to convey useful prognostic information in patients with acute leukemia. For patients with AML, however, the most consistently observed prognostic factors have been age and karyotype. Currently, detection of chromosomal abnormalities at the time of initial diagnosis provides the most useful means of identifying patients at risk of failing induction therapy as well as those likely to have short, intermediate, or prolonged remissions after achieving complete remission. 83 In the future, such prognostic information will become valuable for assigning risk categories and in individualizing postremission therapy for a given patient. The clinical significance of individual cytogenetic abnormalities in AML and possible strategies for postremission therapy are presented in Table 6 .
Application of modern molecular technologies designed to detect minimal residual leukemia may aid clinicians in monitoring disease during and after chemotherapy and could result in the early detection of patients likely to relapse in whom further therapy may be necessary. [84] [85] [86] Immunotherapy may find a niche in the treatment of certain subgroups of acute leukemia and is currently being evaluated. Both interleukin-2 and interferon may play a useful role either in combination with cytotoxic agents or following chemotherapy or BMT to prolong or maintain remission. 87, 88 C A C a n c e r J C l i n 1 9 9 4 ; 4 4 : 3 2 6 -3 5 2
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The hematopoietic growth factors are undergoing extensive clinical investigation in patients with leukemia. Elderly patients and those with recurrent disease are particularly susceptible to the complications of prolonged granulocytopenia following intensive chemotherapy. Initial trials suggested that such patients may benefit from the addition of growth factors designed to stimulate marrow recovery following chemotherapy. 89, 90 However, their use at present cannot be recommended outside the context of a clinical trial. 91 Alternatively, growth factor receptors have been identified on the surfaces of leukemia cells and may be exploited clinically. Exogenous growth factors have been shown to stimulate blast cell C A C a n c e r J C l i n 1 9 9 4 ; 4 4 : 3 2 6 -3 5 92, 93 The concurrent use of growth factors during the administration of cellcycle phase specific chemotherapy such as ara-C may result in enhanced leukemia cell kill. To date, this approach has not resulted in superior remission rates or enhanced survival. 94, 95 Some fraction of patients fail to be cured by therapy as a result of the development and expression of drug resistance by leukemia cells. A major area of research in the last few years has involved the characterization of the mechanisms of drug resistance. The multidrug resistance (MDR) phenotype has been the most widely studied subset in experimental systems. 96 MDR is characterized by impaired accumulation of drug within resistant cells compared with their drug-sensitive counterparts. This is mediated by a membrane glycoprotein (p-glycoprotein) that functions as an active outward transport mechanism for a number of chemotherapeutic agents, such as anthracyclines (e.g., DNR), vinca alkaloids, and epipodophyllotoxins. A variety of drugs, such as verapamil or cyclosporine, have been demonstrated to enhance intracellular accumulation of drug by blocking the action of p-glycoprotein and inhibiting drug efflux from leukemia cells. 97, 98 Trials designed to explore the feasibility and efficacy of using p-glycoprotein blocking agents together with chemotherapy in patients with clinically drug-resistant acute leukemias are under way. In one study, cyclosporine and verapamil led to enhancement of anthracycline accumulation within blast cells, but this did not correlate with response to treatment. 99 Retinoic acid, a derivative of vitamin A, functions in the growth and differentiation of normal tissues. Retinoids have also demonstrated the ability to induce terminal differentiation in leukemia cells in vitro. 100 All-trans-retinoic acid (TRA)
has been used in a number of trials in patients with untreated or relapsed APL. 18, 101 This agent has demonstrated an impressive capacity to induce complete remission, usually within three months, in the vast majority of these patients. TRA is believed to act predominantly by inducing differentiation resulting in programmed cell death rather than by direct cytotoxicity. Successive bone marrow examinations in patients who receive this agent reveal progressive differentiation without hypoplasia. 102 The major side effect, the "TRA Syndrome," is characterized by leukocytosis, pulmonary capillary leak, and renal failure. 103 This may be fatal unless a prompt decrease in leukocyte count is effected by chemotherapy or dexamethasone. The main advantage to TRA lies in avoiding the hemorrhagic complications and pancytopenia associated with cytotoxic chemotherapy. A recent multicenter, randomized trial comparing chemotherapy alone to chemotherapy plus TRA as induction therapy for newly diagnosed APL patients reported increased eventfree survival for patients receiving TRA. 104 The molecular basis of leukemia continues to be pursued. 86 Recently, investigators have attempted to correlate the presence of altered oncogenes with prognosis. In preliminary studies, some mutations (such as RAS) have been correlated with improved survival. 105 Alternatively, high expression of BCL2 has been associated with poor response to chemotherapy. 106 The true clinical significance of these oncogenes awaits further clarification. Further improvements in the outcome of adults with acute leukemia depend on new drug development and innovative strategies to exploit risk factors, molecular analyses, immunotherapy, and cytokines.
